#In Vitro Diagnostics (IVD) Market Share

[marketanalysisdata]

In Vitro Diagnostics (IVD) Industry Size, Trends, Value, Sales and Forecast 2030

The global in vitro diagnostics (IVD) market was valued at approximately USD 77.92 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This growth can be attributed to several factors, including the increasing adoption of IVD technologies due to the rising prevalence of infectious and chronic diseases. The development and integration of automated IVD systems in laboratories and hospitals, which aim to deliver more efficient, accurate, and error-free diagnoses, are also expected to significantly drive market growth. Additionally, the continuous introduction of new IVD products by key industry players contributes to this positive trend. For instance, in November 2023, ARUP Laboratories obtained a CE mark under the EU-IVDR for the AAV5 DetectCDx, a companion diagnostic test that determines the eligibility of patients with severe hemophilia A for BioMarin's gene therapy, Roctavian.

Technological advancements in IVD systems, particularly improvements in accuracy, portability, and cost-effectiveness, are among the high-impact factors influencing this market. Innovations in highly accurate clinical laboratory tests are fostering global adoption of novel IVD diagnostics. For example, in June 2023, Japan's Ministry of Health, Labour, and Welfare granted marketing approval to Toray Industries, Inc. for its Toray APOA2-iTQ, a diagnostic tool used for pancreatic cancer detection. Similarly, in March 2023, Abbott received U.S. FDA clearance for its novel laboratory blood test for Traumatic Brain Injury (TBI). These developments highlight the increasing approval of IVD tests targeting life-threatening diseases, which is expected to create significant opportunities in untapped market segments.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics (IVD) Market

Leading companies in the IVD market are adopting diverse strategies to strengthen their positions, often introducing new products and forming partnerships to attract more customers and meet evolving diagnostic needs. For instance, in March 2023, BD received 510(k) clearance from the U.S. FDA for its BD Vaginal Panel on the BD COR System, aimed at detecting infectious causes of vaginitis. In August 2023, the Precision Medicine Centre (PMC) partnered with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for cancer diagnosis in Northern Ireland. These strategic collaborations and product launches are critical for companies seeking to leverage cutting-edge technologies in diagnostics.

Product Segmentation Insights:

In terms of products, the reagents segment accounted for the largest market share, representing 65.88% of total revenue in 2023. This segment is expected to maintain its dominance, growing at the fastest CAGR from 2024 to 2030. The growth of the reagents segment is driven by extensive research and development (R&D) efforts by key players aimed at developing novel reagents and test kits. For example, in February 2023, BD received market approval for its BD Onclarity HPV Assay, which is used with the ThinPrep Pap Test in the U.S. Ongoing R&D efforts focused on faster cancer detection and precision medicine are prompting companies to concentrate on specialized, profitable areas of the IVD market. In March 2023, QIAGEN formed a partnership with Servier to develop a companion diagnostic test for TIBSOVO, which is indicated for the treatment of acute myeloid leukemia, a type of blood cancer.

The growing demand for precision medicine is expected to further boost the overall demand for these novel reagents and consumables. The instruments segment held the second-largest share of the IVD market in 2023. Increasing approvals of novel IVD instruments are likely to contribute to the segment's growth. For instance, in April 2023, bioMérieux SA submitted a 510(k) application to the U.S. FDA for VITEK REVEAL, a rapid antimicrobial susceptibility testing (AST) system. Moreover, companies are aligning their instrument launches to meet the increasing demand for genetic tests globally. In March 2022, Thermo Fisher Scientific introduced the Ion Torrent Genexus Dx Integrated Sequencer for both research and diagnostic purposes, showcasing the alignment of technological advancements with the growing needs of genetic testing.

In conclusion, the global IVD market is poised for substantial growth, driven by the increasing incidence of infectious and chronic diseases, rising demand for precision medicine, and ongoing advancements in diagnostic technologies. Companies are continuously innovating, launching new products, and forming strategic partnerships to meet the evolving needs of healthcare providers and patients, which will further accelerate market expansion.

Order a free sample PDF of the In Vitro Diagnostics (IVD) Market Intelligence Study, published by Grand View Research.

[marketstudyreport]

In Vitro Diagnostics (IVD) Market Growth Analysis & Forecast Research Report, 2030

The global in vitro diagnostics (IVD) market was valued at approximately USD 77.92 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This growth can be attributed to several factors, including the increasing adoption of IVD technologies due to the rising prevalence of infectious and chronic diseases. The development and integration of automated IVD systems in laboratories and hospitals, which aim to deliver more efficient, accurate, and error-free diagnoses, are also expected to significantly drive market growth. Additionally, the continuous introduction of new IVD products by key industry players contributes to this positive trend. For instance, in November 2023, ARUP Laboratories obtained a CE mark under the EU-IVDR for the AAV5 DetectCDx, a companion diagnostic test that determines the eligibility of patients with severe hemophilia A for BioMarin's gene therapy, Roctavian.

Technological advancements in IVD systems, particularly improvements in accuracy, portability, and cost-effectiveness, are among the high-impact factors influencing this market. Innovations in highly accurate clinical laboratory tests are fostering global adoption of novel IVD diagnostics. For example, in June 2023, Japan's Ministry of Health, Labour, and Welfare granted marketing approval to Toray Industries, Inc. for its Toray APOA2-iTQ, a diagnostic tool used for pancreatic cancer detection. Similarly, in March 2023, Abbott received U.S. FDA clearance for its novel laboratory blood test for Traumatic Brain Injury (TBI). These developments highlight the increasing approval of IVD tests targeting life-threatening diseases, which is expected to create significant opportunities in untapped market segments.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics (IVD) Market

Leading companies in the IVD market are adopting diverse strategies to strengthen their positions, often introducing new products and forming partnerships to attract more customers and meet evolving diagnostic needs. For instance, in March 2023, BD received 510(k) clearance from the U.S. FDA for its BD Vaginal Panel on the BD COR System, aimed at detecting infectious causes of vaginitis. In August 2023, the Precision Medicine Centre (PMC) partnered with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for cancer diagnosis in Northern Ireland. These strategic collaborations and product launches are critical for companies seeking to leverage cutting-edge technologies in diagnostics.

Product Segmentation Insights:

In terms of products, the reagents segment accounted for the largest market share, representing 65.88% of total revenue in 2023. This segment is expected to maintain its dominance, growing at the fastest CAGR from 2024 to 2030. The growth of the reagents segment is driven by extensive research and development (R&D) efforts by key players aimed at developing novel reagents and test kits. For example, in February 2023, BD received market approval for its BD Onclarity HPV Assay, which is used with the ThinPrep Pap Test in the U.S. Ongoing R&D efforts focused on faster cancer detection and precision medicine are prompting companies to concentrate on specialized, profitable areas of the IVD market. In March 2023, QIAGEN formed a partnership with Servier to develop a companion diagnostic test for TIBSOVO, which is indicated for the treatment of acute myeloid leukemia, a type of blood cancer.

The growing demand for precision medicine is expected to further boost the overall demand for these novel reagents and consumables. The instruments segment held the second-largest share of the IVD market in 2023. Increasing approvals of novel IVD instruments are likely to contribute to the segment's growth. For instance, in April 2023, bioMérieux SA submitted a 510(k) application to the U.S. FDA for VITEK REVEAL, a rapid antimicrobial susceptibility testing (AST) system. Moreover, companies are aligning their instrument launches to meet the increasing demand for genetic tests globally. In March 2022, Thermo Fisher Scientific introduced the Ion Torrent Genexus Dx Integrated Sequencer for both research and diagnostic purposes, showcasing the alignment of technological advancements with the growing needs of genetic testing.

In conclusion, the global IVD market is poised for substantial growth, driven by the increasing incidence of infectious and chronic diseases, rising demand for precision medicine, and ongoing advancements in diagnostic technologies. Companies are continuously innovating, launching new products, and forming strategic partnerships to meet the evolving needs of healthcare providers and patients, which will further accelerate market expansion.

Order a free sample PDF of the In Vitro Diagnostics (IVD) Market Intelligence Study, published by Grand View Research.

[mordormr]

Exploring the Growth of the In Vitro Diagnostic (IVD) Market: Key Trends and Insights

The In Vitro Diagnostic (IVD) market is projected to be valued at USD 95.59 billion in 2024, with expectations to grow to USD 125.61 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.62% during the forecast period from 2024 to 2029

The In Vitro Diagnostic (IVD) market has been experiencing robust growth, fueled by advancements in medical technology, an aging population, and increasing demand for early diagnosis and precision medicine. IVD refers to tests conducted on biological samples such as blood, urine, and tissues to diagnose diseases, monitor health conditions, or predict treatment outcomes. These diagnostic tests are critical in guiding clinical decisions and improving patient care.

Key Drivers of the IVD Market

Technological Advancements Cutting-edge technologies like molecular diagnostics, next-generation sequencing (NGS), and point-of-care (POC) testing are revolutionizing the IVD market. Molecular diagnostics, in particular, allow for the detection of specific genetic markers, enabling early detection of diseases such as cancer and genetic disorders. NGS is enhancing personalized medicine by identifying precise mutations in a patient’s DNA, making treatments more targeted and effective.

Aging Population and Chronic Diseases The global aging population is contributing to the rise in chronic diseases such as diabetes, cardiovascular conditions, and cancer. As these conditions require continuous monitoring and management, the demand for IVD tests has increased. For instance, diabetes patients rely on glucose monitoring systems, which are a significant segment of the IVD market. This trend is expected to drive further growth in the coming years.

Rising Demand for Point-of-Care Testing POC testing, which allows for rapid diagnostic results at the patient’s bedside or in non-laboratory settings, is becoming increasingly popular. This technology enables quicker decision-making, especially in emergency situations, and reduces the need for centralized lab facilities. With advancements in POC technology, tests for conditions like COVID-19, diabetes, and infectious diseases are becoming more accessible and efficient.

Personalized Medicine and Companion Diagnostics The shift towards personalized medicine is one of the most significant trends in healthcare today. Companion diagnostics, a segment of IVD, plays a crucial role in determining the suitability of specific therapies based on a patient’s genetic makeup. This approach not only enhances treatment effectiveness but also minimizes adverse drug reactions, improving patient outcomes.

COVID-19 Impact The pandemic significantly boosted the IVD market, particularly in the areas of molecular diagnostics and POC testing. The urgent need for COVID-19 testing drove innovations in rapid testing kits, which have now become a critical part of pandemic management. As healthcare systems around the world continue to prioritize pandemic preparedness, this surge in demand for infectious disease testing is expected to persist.

Challenges Facing the IVD Industry

Despite the positive growth trajectory, the IVD market faces several challenges:

Regulatory Hurdles: IVD products must undergo stringent regulatory approvals before being brought to market, which can delay commercialization. Different regions have varying regulatory requirements, adding complexity for companies operating globally.

Reimbursement Issues: Securing reimbursement for IVD tests, especially in the case of novel diagnostics, can be a barrier to widespread adoption. In many markets, healthcare systems may be slow to integrate these tests into routine care due to cost concerns.

Data Privacy Concerns: As more IVD tests incorporate digital platforms and patient data, concerns over data security and privacy have risen. Ensuring that patient information is protected is critical to maintaining trust in IVD technologies.

Regional Insights

North America: The largest market for IVD, driven by well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and favorable government policies supporting innovation.

Europe: Strong growth is anticipated, particularly in molecular diagnostics and cancer testing. Countries such as Germany, France, and the UK are leading in research and development within the field.

Asia-Pacific: The fastest-growing region due to the rising prevalence of chronic diseases, increasing healthcare expenditure, and improving healthcare infrastructure in countries like China and India.

Future Outlook

The future of the IVD market looks promising, with continued advancements in technology and an increasing focus on precision medicine. The integration of artificial intelligence (AI) and machine learning into diagnostic tools is expected to improve the accuracy of tests and allow for the analysis of large datasets in real-time. Additionally, the ongoing emphasis on personalized healthcare will drive demand for companion diagnostics and genetic testing.

With the global healthcare landscape rapidly evolving, the In Vitro Diagnostic market is well-positioned for sustained growth. Companies investing in innovation, regulatory compliance, and expanding access to diagnostics in emerging markets will be the key players shaping the future of this dynamic industry.

Conclusion

The In Vitro Diagnostic market is a vital part of modern healthcare, providing the tools needed for accurate and timely diagnosis of diseases. As new technologies emerge and patient demand for personalized care grows, the IVD industry is set to expand further, offering innovative solutions that enhance healthcare outcomes and improve the quality of life for patients worldwide.

[renubresearch]

United States In-Vitro Diagnostics Market will be US$ 56.52 Billion in 2030

In vitro diagnostics (IVD) entails laboratory-based medical assessments performed outside of a living organism, making use of additives extracted from the human body or other resources. Vital for healthcare, IVD aids in disease analysis, treatment, and monitoring with the aid of studying samples like blood, urine, and tissues. It encompasses diverse technologies along with molecular diagnostics,…

[tbrcresearchreport]

The Business Research Company offers in vitro diagnostics ivd quality control market research report 2023 with industry size, share, segments and market growth

[joeypetter]

Global In Vitro Diagnostics (IVD) Market Report 2022| Research Analysis with Trends, Segmentation, Share and Forecast by 2030| By R&I

The report is titled as ‘In Vitro Diagnostics Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the In Vitro Diagnostics market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. In Vitro Diagnostics market is expected to grow with significant rate in the near future.

The global In Vitro Diagnostics (IVD) market in 2020 is estimated for more than US$ 70,561.9 Mn and expected to reach a value of US$ 1,03,310.9 Mn by 2028 with a significant CAGR of 4.9%.

Request a Sample Copy of this Report @: https://reportsandinsights.com/sample-request/1256

In Vitro Diagnostics Market Dynamics

In-vitro diagnostics are tests performed in laboratories on biological samples such as blood, urine, tissue, etc. In vitro diagnostic are not only used for diagnosis but also provides useful information on monitoring of disease and treatment. Two-thirds of today’s clinical diagnoses involve in vitro diagnostics, hence are referred to as the backbone of healthcare.

In-vitro diagnostics market has witnessed substantial growth in last decade owing to technological advancements in testing methods as well as in analyzer instruments. According to the EPRS report, there are over 40,000 different IVD products available in the European market and per capita annual spending on IVD is approximately US$ 26. In-vitro diagnostics help to reduce the healthcare cost by making treatments more efficient and precise.

Evolving regulations for in-vitro diagnostics is the major driving force for market growth over the forecast period. For instance, regulation of medical devices in the European Union (EU) is undergoing a significant transformation with expanding the scope for in vitro diagnostics, which is expected to impact the increased product approvals for IVD in the region. Significant progress in point-of-care testing is another factor driving the growth of the global in-vitro diagnostics market. Introduction of molecular based assays and identification of range of biomarkers has opened up huge new opportunity for growth of global in-vitro diagnostics market.

MMC Overview on In Vitro Diagnostics Market Report

The non-identical approach of Reports and Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.

A research report on the In Vitro Diagnostics market by Reports and Insights is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Wish to Know More About the Study? Click here to get a Report Description: https://reportsandinsights.com/pressrelease/global-in-vitro-diagnostics-market

In Vitro Diagnostics Market Segmentation

The global in vitro diagnostics market is segmented on the basis of product type, technology, end user and region. On the basis of product type, in vitro diagnostics market is segmented as reagents and kits, analyze, and consumables. Based on technology, global market is segmented as immunochemistry, molecular diagnostics, hematology, point-of-care diagnostics, tissue diagnostics and clinical chemistry. On the basis of end user, global in vitro diagnostics market is segmented into hospitals, diagnostic centers, clinics, home care settings and others.

By Products & Services

Reagents & Kits

Instruments

Fully Automated Instruments

Semi-Automated Instruments

Other Instruments

Data Management Software

Services

By Technology

mmunoassay/Immunochemistry

Enzyme-Linked Immunosorbent Assay

hemiluminescence Immunoassays

Fluorescence Immunoassays

Colorimetric Immunoassays

Radioimmunoassay

Rapid Test

Western Blotting

Enzyme-Linked Immunospot Assays

Clinical Chemistry

Basic Metabolic Panel

Electrolyte Panel

Liver Panel

Lipid Profile

Renal Profile

Thyroid Function Panel

Specialty Chemical Tests

Molecular Diagnostics

Polymerase Chain Reaction

Isothermal Nucleic Acid Amplification Technology

Microarray

Hybridization

DNA Sequencing & Next-Generation Sequencing

Other Mdx Technologies

Microbiology

Hematology

Coagulation and Hemostasis

Urinalysis

Other IVD Technologies

By Application

 Infectious Diseases

 Diabetes

 Oncology

 Cardiology

 Autoimmune Diseases

 Nephrology

 Drug Testing/Pharmacogenomics

 HIV/Aids

 Other Applications

By End User

Hospitals

Laboratories

Large/Reference Laboratories

Medium-Sized Laboratories

Small Laboratories

Point-Of-Care Testing

Patient Self-Testing

Academic Institutes

Other End Users

By Region

 North America

 Latin America

 Europe

 Asia Pacific

 Middle East

 Africa

In Vitro Diagnostics Market Competitive Landscape

Global market for in vitro diagnostics is dominated by Abbott Laboratories, Merck KGaG, F. Hoffman-La Roche AG, Becton Dickinson & Company, Danaher Corporation, Thermo Fisher Scientific Inc., Qiagen N.V., Diasorin S.P.A., biomerieux SA, Alere Inc., Bayer AG, Bio-Rad Laboratories Inc., Sysmex Corporation, etc. to name a few.

To view Top Players, Segmentation and other Statistics of In Vitro Diagnostics (IVD) Industry, Get Sample Report @: https://reportsandinsights.com/sample-request/1256

About Reports and Insights:

Reports and Insights is one of the leading market research companies which offers syndicate and consulting research around the globe. At Reports and Insights, we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us:

Neil Jonathan

1820 Avenue M, Brooklyn

NY 11230, United States

+1-(718) 312-8686

Find Us on LinkedIn: www.linkedin.com/company/report-and-insights/

View Latest Market Updates At: https://marketsresearchanalytics.com

[latestmarketresearchnews]

In Vitro Diagnostics (IVD) Industry Sales, Demand, Regional Outlook And Supply Chain Analysis till 2030

The global in vitro diagnostics (IVD) market reached an estimated size of USD 77.92 billion in 2023, with expectations for a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This market growth is primarily driven by the increasing use of IVD tools due to rising cases of infectious and chronic diseases worldwide. Automated IVD systems are becoming more common in hospitals and laboratories, as they provide accurate, fast, and error-free diagnoses, helping meet the growing demand for efficient healthcare services. Additionally, IVD market expansion is fueled by frequent product launches from key industry players. For example, in November 2023, ARUP Laboratories received a CE mark from the EU-IVDR for AAV5 DetectCDx, a companion diagnostic that helps identify eligibility for severe hemophilia Some patients to receive BioMarin’s gene therapy, Roctavian.

Major companies in the IVD market are employing various strategies to strengthen their position and bring more advanced and diverse products to their customers. New product launches and partnerships are among the most common tactics. For instance, in March 2023, BD received FDA 510(k) clearance for the BD Vaginal Panel on its BD COR System, a tool designed to detect infectious causes of vaginitis. In another instance, in August 2023, the Precision Medicine Centre (PMC) partnered with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for cancer diagnosis in Northern Ireland. These partnerships and product developments highlight how key players are focused on expanding their diagnostic offerings to meet growing healthcare needs.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics (IVD) Market

Supportive initiatives from government and non-governmental bodies are also contributing to the market's growth by enhancing access to essential diagnostic tools. In October 2023, the World Health Organization (WHO) released an updated Essential Diagnostics List (EDL), a comprehensive catalog of vital IVD products that aids countries in making informed decisions on diagnostic tools. This list provides evidence-based recommendations, ensuring that essential diagnostic products are accessible to the people who need them most. Additionally, in August 2023, the Africa CDC collaborated with the Africa Development Agency-New Partnership for Africa's Development (AUDA-NEPAD) to improve access to diagnostic tests across the African continent. Such initiatives are expected to further support the expansion of the IVD market, especially in regions with limited healthcare resources.

The global aging population, coupled with growing awareness of early disease detection, has led to an increase in routine check-ups. This trend is particularly relevant because the majority of deaths due to infections and chronic conditions occur in people over 75. According to the UK's Office for Budget Responsibility, healthcare costs have seen a significant rise, which can place economic strain on countries with rapidly aging populations. However, these increased expenditures are likely to boost the IVD market, as diagnostic testing becomes essential in managing the healthcare needs of older adults.

End-use Segmentation Insights:

Hospitals represented the largest revenue share in the IVD market in 2023, largely due to an increase in hospital admissions requiring rapid diagnostic support. The continuous development of healthcare infrastructure, supported by government initiatives, is further improving hospital facilities, thereby increasing demand for hospital-based IVD testing. IVD tests are frequently purchased by hospitals and are utilized in large volumes due to their critical role in providing fast, accurate results for patient care. In the U.S. alone, there are over 6,129 hospitals, all of which rely on IVD tests for essential decision-making in patient care.

In December 2023, the American Hospital Association advocated to the FDA that regulatory requirements for devices should not apply to hospitals' laboratory-developed tests (LDTs), which could allow hospitals greater flexibility in their use of in-house diagnostic tools. Meanwhile, the homecare segment is anticipated to see high growth from 2024 to 2030, driven by the aging population and increasing demand for at-home diagnostic devices. There is a particular need for novel molecular diagnostic and immunoassay platforms that enable patients to perform self-tests conveniently at home. For example, in February 2023, the FDA granted Emergency Use Authorization (EUA) to the first over-the-counter (OTC) home diagnostic test capable of distinguishing between influenza A, influenza B, and SARS-CoV-2 (the virus causing COVID-19). This authorization demonstrates the shift towards providing individuals with more autonomy in managing their health through accessible at-home testing solutions.

Order a free sample PDF of the In Vitro Diagnostics (IVD) Market Intelligence Study, published by Grand View Research.

[researchreportinsight]

In Vitro Diagnostics (IVD) Industry Growth Analysis & Forecast Research Report, 2030

The global in vitro diagnostics (IVD) market reached an estimated size of USD 77.92 billion in 2023, with expectations for a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. This market growth is primarily driven by the increasing use of IVD tools due to rising cases of infectious and chronic diseases worldwide. Automated IVD systems are becoming more common in hospitals and laboratories, as they provide accurate, fast, and error-free diagnoses, helping meet the growing demand for efficient healthcare services. Additionally, IVD market expansion is fueled by frequent product launches from key industry players. For example, in November 2023, ARUP Laboratories received a CE mark from the EU-IVDR for AAV5 DetectCDx, a companion diagnostic that helps identify eligibility for severe hemophilia Some patients to receive BioMarin’s gene therapy, Roctavian.

Major companies in the IVD market are employing various strategies to strengthen their position and bring more advanced and diverse products to their customers. New product launches and partnerships are among the most common tactics. For instance, in March 2023, BD received FDA 510(k) clearance for the BD Vaginal Panel on its BD COR System, a tool designed to detect infectious causes of vaginitis. In another instance, in August 2023, the Precision Medicine Centre (PMC) partnered with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for cancer diagnosis in Northern Ireland. These partnerships and product developments highlight how key players are focused on expanding their diagnostic offerings to meet growing healthcare needs.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics (IVD) Market

Supportive initiatives from government and non-governmental bodies are also contributing to the market's growth by enhancing access to essential diagnostic tools. In October 2023, the World Health Organization (WHO) released an updated Essential Diagnostics List (EDL), a comprehensive catalog of vital IVD products that aids countries in making informed decisions on diagnostic tools. This list provides evidence-based recommendations, ensuring that essential diagnostic products are accessible to the people who need them most. Additionally, in August 2023, the Africa CDC collaborated with the Africa Development Agency-New Partnership for Africa's Development (AUDA-NEPAD) to improve access to diagnostic tests across the African continent. Such initiatives are expected to further support the expansion of the IVD market, especially in regions with limited healthcare resources.

The global aging population, coupled with growing awareness of early disease detection, has led to an increase in routine check-ups. This trend is particularly relevant because the majority of deaths due to infections and chronic conditions occur in people over 75. According to the UK's Office for Budget Responsibility, healthcare costs have seen a significant rise, which can place economic strain on countries with rapidly aging populations. However, these increased expenditures are likely to boost the IVD market, as diagnostic testing becomes essential in managing the healthcare needs of older adults.

End-use Segmentation Insights:

Hospitals represented the largest revenue share in the IVD market in 2023, largely due to an increase in hospital admissions requiring rapid diagnostic support. The continuous development of healthcare infrastructure, supported by government initiatives, is further improving hospital facilities, thereby increasing demand for hospital-based IVD testing. IVD tests are frequently purchased by hospitals and are utilized in large volumes due to their critical role in providing fast, accurate results for patient care. In the U.S. alone, there are over 6,129 hospitals, all of which rely on IVD tests for essential decision-making in patient care.

In December 2023, the American Hospital Association advocated to the FDA that regulatory requirements for devices should not apply to hospitals' laboratory-developed tests (LDTs), which could allow hospitals greater flexibility in their use of in-house diagnostic tools. Meanwhile, the homecare segment is anticipated to see high growth from 2024 to 2030, driven by the aging population and increasing demand for at-home diagnostic devices. There is a particular need for novel molecular diagnostic and immunoassay platforms that enable patients to perform self-tests conveniently at home. For example, in February 2023, the FDA granted Emergency Use Authorization (EUA) to the first over-the-counter (OTC) home diagnostic test capable of distinguishing between influenza A, influenza B, and SARS-CoV-2 (the virus causing COVID-19). This authorization demonstrates the shift towards providing individuals with more autonomy in managing their health through accessible at-home testing solutions.

Order a free sample PDF of the In Vitro Diagnostics (IVD) Market Intelligence Study, published by Grand View Research.

[ashwetu]

Meticulous Research® Forecasts Middle East IVD Market to Reach $2.15 Billion by 2031

 The report highlights market dynamics, growth drivers, key challenges, and opportunities across the region.

Meticulous Research®, a globally recognized leader in market intelligence, has released a new report titled, "Middle East IVD Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab) - Forecast to 2031." According to the findings, the Middle East in vitro diagnostics (IVD) market is projected to reach $2.15 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031.

Key Market Drivers

The growth of the Middle East IVD market is driven by several factors, including the rising prevalence of chronic and infectious diseases, increased demand for point-of-care (PoC) and rapid diagnostic solutions, expanding healthcare expenditures, and an aging population. Moreover, growing healthcare awareness, especially in countries such as the UAE and Saudi Arabia, is also contributing to market expansion. However, the high costs associated with IVD tests and inconsistencies in results from rapid diagnostic tests present challenges to sustained growth.

Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5764

Emerging Opportunities

Increasing awareness around early disease detection and personalized medicine, particularly in the UAE and Saudi Arabia, is creating opportunities for market players. These regions are witnessing an uptick in the adoption of advanced diagnostic technologies, which is expected to fuel demand in the coming years. Nonetheless, issues such as false positives in immunoassays and PoC tests remain significant hurdles that stakeholders need to address.

Competitive Landscape

The Middle East IVD market is dominated by global healthcare giants such as Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), BioMérieux S.A. (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche (Switzerland), and Siemens Healthineers AG (Germany). Other key players include QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (U.S.), and Bio-Rad Laboratories, Inc. (U.S.), among others.

Request Sample Report Here: https://www.meticulousresearch.com/request-sample-report/cp_id=5764

Market Segmentation Insights

The report provides a detailed breakdown of the Middle East IVD market based on various parameters:

Offerings: The kits and reagents segment is expected to register the highest growth rate due to their extensive use in diagnosing chronic and infectious diseases. This is attributed to the increasing volume of tests for diseases such as HIV and influenza, alongside growing consumer awareness of self-testing options.

Technologies: Molecular diagnostics, including PCR and next-generation sequencing (NGS), is expected to capture the largest market share in 2024, driven by the rising prevalence of communicable and non-communicable diseases and the need for high-volume, accurate testing.

Applications: Infectious disease testing is set to dominate the market, with respiratory infections, hepatitis, HIV, and sexually transmitted diseases (STDs) being the primary drivers. The region's aging population and increasing healthcare demand are also contributing to the rise in testing.

Diagnostic Approach: Point-of-care testing is expected to exhibit the highest growth, propelled by the increasing burden of chronic diseases and the launch of innovative PoC diagnostics by market leaders.

End Users: Hospitals and clinics will continue to be the largest segment, performing a wide range of diagnostic tests for various medical conditions, particularly in urban areas where access to healthcare services is more robust.

Access Full Report Details Here : https://www.meticulousresearch.com/request-sample-report/cp_id=5764

Country Insights

Among the Middle Eastern countries, Saudi Arabia is projected to dominate the IVD market in 2024, largely due to its rapidly aging population, the high incidence of chronic and infectious diseases, and the growing adoption of self-testing. The Kingdom’s healthcare sector is also experiencing a boost thanks to its Vision 2030 strategy, which aims to elevate healthcare standards and increase investments in medical technologies. Healthcare expenditure in Saudi Arabia is expected to grow annually by 3.0% from 2022 to 2025, further supporting market growth.

Conclusion

The Middle East IVD market presents lucrative opportunities for growth, driven by evolving healthcare needs, technological advancements, and rising awareness around early disease detection. However, market players must navigate challenges related to pricing and diagnostic accuracy to fully capitalize on the region’s potential.

Quick Buy: https://www.meticulousresearch.com/Checkout/69732912

About Meticulous Research®

Meticulous Research® is a globally recognized market research and consulting firm known for delivering in-depth insights across a variety of industries. We provide high-quality market intelligence and strategic guidance to clients across the globe.

Contact Information Email: sales@meticulousresearch.com Sales Inquiry: +1-646-781-8004 Connect with us on LinkedIn: Meticulous Research® LinkedIn

[industrynewsupdates]

In Vitro Diagnostics Market Size and Regional Outlook Analysis 2024 - 2030

The global in vitro diagnostics market size is expected to reach USD 101.58 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 4.4% over the forecast period driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.

These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics Market

Detailed Segmentation:

Market Characteristics

Market growth stage is medium, and the pace of the market growth is decelerating. Decreasing demand for COVID-19 tests is hampering the growth. The market is characterized by a high degree of innovation owing to the increasing introduction of novel molecular diagnostics and immunoassay tests for multiple disease indications. Moreover, increasing demand for patient-centric tests is encouraging market players to develop technologically advanced products.

Product Insights

The reagents segment held the largest share of 65.88% of the overall revenue in 2023. The segment is expected to retain its dominance growing at the fastest CAGR from 2024 to 2030 owing to the extensive R&D initiatives undertaken by major players to develop novel reagents and test kits. For instance, in February 2023, BD received the market approval for the BD Onclarity HPV Assay to be used with the ThinPrep Pap Test in the U.S. The increasing R&D activities to enable faster cancer detection and precision medicine are allowing companies to focus on niche profitable areas in the IVD business. For instance, in March 2023, QIAGEN partnered with Servier to develop a companion diagnostic test for TIBSOVO, indicated for treating the blood cancer acute myeloid leukemia.

Technology Insights

The immunoassay segment accounted for the largest revenue share in 2023. Increasing incidence of chronic & communicable diseases and rising need for early diagnosis are among the key factors leading to an increase in demand for immunological methods, including different types of Enzyme-Linked Immunosorbent Assays (ELISAs). Moreover, key players are focused on R&D pertaining to development of new immunological diagnostic instruments and tests for IVD applications. For instance, in October 2023, Sysmex Corporation and Fujirebio Holdings, Inc. collaborated to enhance their R&D, production, clinical development, and marketing activities in immunoassay.

End-use Insights

The hospitals segment held the largest revenue share in 2023 owing to a rise in the rate of hospitalizations that require support from faster diagnostics. Moreover, the ongoing development of healthcare infrastructure and favorable initiatives taken by government bodies are anticipated to enhance the existing hospital facilities. Thus, the demand for hospital-based IVD tests is increasing. Most IVD devices are purchased by hospitals and used in significant volumes. In 2023, there are over 6,129 hospitals in the U.S. that require constant aid from IVD for critical decision-making, as IVD tests provide faster and more accurate results.

Test Location Insights

The others (lab-based tests) segment accounted for the largest revenue share in 2023. A large number of test analyses at one time and the higher accuracy of laboratory-based tests make them more reliable compared to PoC and home tests, giving segment a competitive edge over the other two segments. Moreover, the availability of tests that allow for sample collection at home and sending it to the laboratories for testing makes testing highly convenient for patients.

Application Insights

The infectious diseases segment dominated the market in 2023. The outbreak of the COVID-19 pandemic increased the segment share significantly in recent years. Moreover, key players are introducing novel testing products to improve access to high-quality, innovative laboratory services for patients & healthcare providers. For instance, in February 2023, BD received EUA from the U.S. FDA for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV). Such initiatives by key players to strengthen their presence are expected to drive market growth.

Regional Insights

North America dominated the market and accounted for a share of 42.28% in 2023. The region is estimated to retain its leading market position throughout the forecast period. The market in this region is collectively driven by factors, such as the rising incidence of chronic diseases, presence of strong players, increasing number of novel test launches, and supportive government funding. For instance, in January 2023, BD and CerTest Biotec received EUA from the U.S. FDA for a PCR test for Mpox virus detection in the U.S. Moreover, the increasing requirement for genetic testing for personalized health care, such as that for diabetes and cancer, is expected to drive market growth in North America.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global hepatitis diagnostic market size was valued at USD 3.82 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030.

• The global hematology diagnostics market size was valued at USD 7.54 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030. 

Key Companies & Market Share Insights

Some of the key players operating in the in vitro diagnostics market include F. Hoffmann-La Roche Ltd.; Abbott; Quest Diagnostics Inc.; and Danaher. Market players are adopting various strategies, such as new product launches, mergers & acquisitions, and partnerships, to strengthen their product portfolios and offer diverse technologically advanced & innovative products.

Key In Vitro Diagnostics (IVD) Companies:

• Abbott

• bioMérieux SA

• QuidelOrtho Corporation

• Siemens Healthineers AG

• Bio-Rad Laboratories, Inc.

• Qiagen

• Sysmex Corporation

• Charles River Laboratories

• Quest Diagnostics Incorporated

• Agilent Technologies, Inc.

• Danaher Corporation

• BD

• F. Hoffmann-La Roche Ltd.

In Vitro Diagnostics Market Segmentation

Grand View Research has segmented the global in vitro diagnostics (IVD) market report based on product, technology, application, end-use, test location, and region:

IVD Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Reagents

• Services

IVD Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Immunoassay

o Instruments

o Reagents

o Services

• Hematology

o Instruments

o Reagents

o Services

• Clinical Chemistry

o Instruments

o Reagents

o Services

• Molecular Diagnostics

o Instruments

o Reagents

o Services

• Coagulation

o Instruments

o Reagents

o Services

• Microbiology

o Instruments

o Reagents

o Services

• Others

o Instruments

o Reagents

o Services

IVD Application Outlook (Revenue, USD Million, 2018 - 2030)

• Infectious Diseases

• Diabetes

• Oncology

• Cardiology

• Nephrology

• Autoimmune Diseases

• Drug Testing

• Others

IVD Test Location Outlook (Revenue, USD Million, 2018 - 2030)

• Point of Care

• Home-care

• Others

IVD End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Laboratory

• Home-care

• Others

IVD Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Spain

o Italy

o Russia

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o South Korea

o Australia

o Thailand

o Singapore

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.

Recent Developments

• In December 2023, ARUP Laboratories and Medicover collaborated to provide diagnostic and healthcare services in Europe. ARUP Laboratories has developed AAV5 DetectCDx in collaboration with BioMarin Pharmaceutical Inc. to select therapies for severe hemophilia A patients

• In November 2023, Veracyte joined Illumina to develop molecular tests for decentralized IVD applications. Companies are focusing on the development of Prosigna breast cancer and Percepta nasal swab tests of Veracyte

• In October 2023, Promega Corporation announced its plan to develop and commercialize companion diagnostics kits with GSK Plc to identify cancer patients with MSI-H solid tumors

• In February 2023, Unilabs announced investing over USD 200 million in Siemens Healthineers' technology and acquiring more than 400 laboratory analyzers to strengthen its laboratory infrastructure

• In February 2023, F. Hoffmann-La Roche Ltd. collaborated with Janssen Biotech Inc. to develop companion diagnostics for targeted therapies. Companion diagnostic technologies include digital pathology, NGS, PCR, immunoassays, and immunohistochemistry

[market-spy]

Pediatric Medical Devices Market Analysis, Size, Share & Trends | 2031

In recent years, the global Pediatric Medical Devices Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Pediatric Medical Devices Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five Forces Analysis, PESTLE Analysis, Value Chain Analysis, 4 Ps' Analysis, Market Attractiveness Analysis, BPS Analysis, Ecosystem Analysis. Get Your Free Sample Report Here @ https://www.skyquestt.com/sample-request/pediatric-medical-devices-market

The global pediatric medical devices market reached a valuation of approximately USD 28.4 billion in 2023. Projections indicate that the market is poised to experience steady growth over the next decade, with a projected compound annual growth rate (CAGR) of 7.8% from 2024 to 2031. The new study offers a brief evaluation of the Pediatric Medical Devices Market statistics, which are subdivided into the regions, countries as well as subregions. This report is helpful to remark the possible estimations and projection regarding the growth strategies of the global Pediatric Medical Devices Market. It also summarizes possible profit opportunities, sales/demand, production as well as consumption analysis, in involvement to Pediatric Medical Devices industry share in each nation and sub-region. The geographical segment of the Pediatric Medical Devices Market report illustrates the industry share as well as growth rates of each region during the estimated period from 2024 to 2031. Global urbanization and rapid industrialization have increased the need for new market Growth. This has prompted a rise in the use of Pediatric Medical Devices. Additionally, massive amounts of money are being spent by governments and the private sector globally on Pediatric Medical Devices industry, which is further boosting the market's expansion. The amount that regional governments are investing to improve the current investment is increasing as part of their global market plans. The whole research report on the Pediatric Medical Devices Market concentrated on the valuable data and various other factors. Additionally, the report delivers a comprehensive overview, pie charts, tables, diagrams, and tables to assist the growth of the Pediatric Medical Devices Market. Market Segments covered: By Product - Cardiology Devices, In Vitro Diagnostic (IVD) Devices, Diagnostic Imaging Devices, Anesthesia & Respiratory Care Devices, Neonatal ICU Devices, Others By End-user - Hospitals, Pediatric Clinics, Ambulatory Surgical Centers, Others By Regional - North America, Europe, Asia Pacific, Latin America

To establish the important thing traits, Ask Our Experts @ https://www.skyquestt.com/speak-with-analyst/pediatric-medical-devices-market

Profitable players of the Pediatric Medical Devices Market are: TSE MEDICAL Ningbo David Medical Device Co. Ltd Hamilton Medical GE Healthcare Fritz Stephan GmbH Phoenix Medical Systems Pvt Ltd Novonate Inc. Trimpeks Atom Medical Corporation Abbott Medtronic PLC

Essential regions of the Pediatric Medical Devices Market are: Pediatric Medical Devices North America Market includes (Canada, Mexico, USA) Pediatric Medical Devices Europe Market includes (Germany, France, Great Britain, Italy, Spain, Russia) Pediatric Medical Devices Asia-Pacific Market includes (China, Japan, India, South Korea, Australia) Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa) Pediatric Medical Devices South America Market includes (Brazil, Argentina) FAQs: - What are the sales, production, consumption, imports, and exports of the global market (North America, Europe, Asia-Pacific, South America, Middle East, and Africa)? Who are the major manufacturers who dominate the world market? What are their current capacity, production, sales, pricing, cost, gross, and revenue operating levels? What are the market's risks and opportunities? What's more, it likewise covers the request and give of the promoting research concentrate in the assessed figure time frame. Explained investigation of the market players with their profile, deals examination and serious scene is given in the report. Besides, organization, joint effort and consolidations in the business are referenced for the accommodation of the investigation of the global Pediatric Medical Devices industry.

Take Action Now: Secure Your Pediatric Medical Devices Market Today - https://www.skyquestt.com/buy-now/pediatric-medical-devices-market Pivotal questions answered in the global Pediatric Medical Devices Market report: What are the major value propositions of the Pediatric Medical Devices Market? What are the new strategical frameworks that are mobilized among players to accomplish resilience in the wake of the COVID-19 pandemic? What technologies are expected to adopt the new regulations in Pediatric Medical Devices report? What are the key collaborations generated by the vendors to consolidate their position in the Pediatric Medical Devices Market? What are the vital offerings new entrants concentrate on to implement unique positioning strategies? What are the futuristic prospects of the Pediatric Medical Devices Market across the globe? Looking ahead, the Pediatric Medical Devices Market is poised for continued growth, driven by evolving consumer preferences and ongoing innovations. The trend towards sustainability is expected to strengthen, with more consumers seeking products that align with their values. Additionally, the integration of advanced technologies and digital platforms will likely further enhance market accessibility and consumer engagement. The global Pediatric Medical Devices Market is a dynamic and evolving landscape, shaped by a confluence of trends and factors. Get Complete Report Pediatric Medical Devices Market 2024 for Better Understanding @ https://www.skyquestt.com/report/pediatric-medical-devices-market

Contact: Mr. Jagraj Singh Skyquest Technology 1 Apache Way, Westford, Massachusetts 01886 USA (+1) 351–333–4748 Email: sales@skyquestt.com Visit Our Website: https://www.skyquestt.com/ About Us: SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology. We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.

[renubresearch]

Saudi Arabia IVD Market will be US$ 1.48 Billion in 2030

According to Renub Research, the Saudi Arabia IVD Market is forecasted to reach approximately US$ 1.48 Billion by 2030. Saudi Arabia is poised to become the world’s fastest-growing major economy in 2022, surpassing other Middle Eastern countries and major emerging economies. In vitro diagnostics (IVD) play a crucial role in monitoring overall health. These tests involve examining samples such as…

[marketingreportz]

Companion Diagnostics Market - Forecast(2024 - 2030)

 Companion Diagnostic Market Overview:

The Harvard University, while addressing the risk associated with reactions of new drugs prescription, has stated some overwhelming facts. According to their findings, even properly prescribed drugs causes about 1.9 million hospitalizations a year and about 128,000 people die from drugs prescribed to them.[1] Such epidemic condition is being tailgated by the need of safe and effective and specific use of the drug. Owing to such demands, companion diagnostic drug market is poised for exponential growth. Companion diagnostics is an in-vitro diagnostic tool that assists physicians in optimizing treatment decisions for their patients and is crucial for myriad of cancer and other therapies. Riding on the back of economic burden of global healthcare and with abundant potential to restrict the liability, companion diagnostic market size is estimated to be $2,950 million as of 2018.

Inquiry Before Buying

Companion Diagnostic Market Outlook:

Companion diagnostic (CDx) is a diagnostic test used as an associate to a therapeutic drug to regulate its applicability to an individual person. It involves multiple monitoring methods including immunohistochemistry (IHC), polymerase chain Reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), and gene sequencing. The companion diagnostics uses technologies such as molecular biology technique, drug and diagnostic technology, and oncology therapy for the treatment of colorectal cancer, breast cancer, and other chronic diseases.

 An acute analysis of the region-wise companion diagnostic market share concluded with reckoning North America as the most lucrative market for CDx. This region with cutting-edge healthcare technology in the United States and Canada generates 41% of the global companion diagnostic market demand for alarming need for cancer diagnosis and treatment. According to the American Cancer Society, prostate cancer is the most common cancer among males (19%), followed by lung (14%) and colorectal (9%) cancers and among females, breast (30%), lung (12%), and colorectal (8%) cancers are the most common. Increasing instances of cancer along with neurological disorders, infectious diseases, Hepatitis A is augmenting the North American companion diagnostic market.

Companion diagnostic market with abundant potential as an effective tool for personalized medicine has found a tremendous scope of application in pharmaceuticals, laboratories, research institutes and hospitals. Hospital as an end-user industry is the leading segment progressing with an application CAGR of 12.5% going through 2025. Hospitalized patients account for a total of 2.74 million serious adverse drug reactions. Each CDx test is specifically designed to be corresponding with an exact drug. Such tests can also save significant hospital expenditure by targeting specific patients with the most effective therapy.

Request Sample

 Companion Diagnostic Market Trends and Growth Drivers:

·         The necessity for personalized therapeutics for the cumulative geriatrics population and the increasing figure of diagnostics centers in both the developed and developing economies is predominant to determine profits in the global companion diagnostics market.

·         FDA had issued "Guidance for Industry: In Vitro Companion Diagnostic Devices," to assist syndicates recognize the necessity for companion diagnostics at an initial stage in the drug development procedure and to strategize for co-development of the drug and companion diagnostic test.

 On July 15, 2016, FDA introduced the draft regulation, "Principles for Co-development of an In Vitro Companion Diagnostic Device with a Therapeutic Product." This guidance text is envisioned to be a practical guide to support therapeutic product promoters and IVD sponsors in evolving a therapeutic product and an associated IVD companion diagnostic. The scientific progressions in the in-situ hybridization and automated silver-enhanced in-situ hybridization (SISH) for the monitoring of genes is trending in the global companion diagnostics market.

Schedule a Call

 Companion Diagnostic Market Players Perspective:

Some of the key players influencing the global market are:-  Abbott Laboratories, Agilent Technologies, biomerieux, Bio-Genex Laboratories, Danaher Corporation, GE Healthcare, Myriad Genetics, Inc., QIAGEN N.V., R-Biopharm AG, and Roche Diagnostics.

In April 2017, Abbott acquired Alere for a new price of about $5.3 billion. Alere is the global leader in point of care diagnostics focused on the areas of infectious disease, molecular, cardiometabolic and toxicology. The collective business will offer the biggest point of care menu of infectious disease, molecular, cardiometabolic and toxicology testing. Abbott's platforms will be expanded to comprise benchtop and rapid strip tests.

Buy Now

 Companion Diagnostic Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the companion diagnostic market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the various diagnostics in companion diagnostic market, and their specific advantages.

[globalgrowthinsights]

Train Communication Gateways Systems Market Trends, Demand & Future Scope till 2032

Train Communication Gateways Systems Market provides in-depth analysis of the market state of Train Communication Gateways Systems manufacturers, including best facts and figures, overview, definition, SWOT analysis, expert opinions, and the most current global developments. The research also calculates market size, price, revenue, cost structure, gross margin, sales, and market share, as well as forecasts and growth rates. The report assists in determining the revenue earned by the selling of this report and technology across different application areas.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Train Communication Gateways Systems in these regions till the forecast period

North America

Middle East and Africa

Asia-Pacific

South America

Europe

Key Attentions of Train Communication Gateways Systems Market Report:

The report offers a comprehensive and broad perspective on the global Train Communication Gateways Systems Market.

The market statistics represented in different Train Communication Gateways Systems segments offers complete industry picture.

Market growth drivers, challenges affecting the development of Train Communication Gateways Systems are analyzed in detail.

The report will help in the analysis of major competitive market scenario, market dynamics of Train Communication Gateways Systems.

Major stakeholders, key companies Train Communication Gateways Systems, investment feasibility and new market entrants study is offered.

Development scope of Train Communication Gateways Systems in each market segment is covered in this report. The macro and micro-economic factors affecting the Train Communication Gateways Systems Market

Advancement is elaborated in this report. The upstream and downstream components of Train Communication Gateways Systems and a comprehensive value chain are explained.

Browse More Details On This Report at @https://www.globalgrowthinsights.com/market-reports/train-communication-gateways-systems-market-100575

 Global Growth Insights

Web: https://www.globalgrowthinsights.com

Our Other Reports:

Car Collision Avoidance Radar MarketMarket Growth

Membrane Pressure Vessel MarketMarket Analysis

In Vitro Diagnostics (IVD) Quality Control MarketMarket Size

Global Animal Drug Compounding MarketMarket Share

Global Polyhydroxyalkanoate (PHA) MarketMarket Growth

Digital Media MarketMarket

Domestic Booster Pump MarketMarket Share

Pv Solar Energy Charge Controller MarketMarket Growth Rate

Cloud Native Platform and Container Management Platforms MarketMarket Forecast

Global Artificial Intelligence in Agriculture MarketMarket Size

Face Mist MarketMarket Growth

Electric Power Distribution Equipment MarketMarket Analysis

Cloud ERP MarketMarket Size

Global Down Jacket MarketMarket Share

Global Laboratory Information System (LIS) MarketMarket Growth

Switch Mode Power Supply Transformers MarketMarket

Commercial Clothes Dryer MarketMarket Share

Podcasting MarketMarket Growth Rate

CBD Skin Care MarketMarket Forecast

Global Demand Side Platform (DSP) System MarketMarket Size

Collaborative Robot MarketMarket Growth

Fast Food and Quick Service Restaurant MarketMarket Analysis

Automotive Lifts & Car Parking Lifts MarketMarket Size

Global Active Electronically Scanned Array (AESA) Radars MarketMarket Share

Global Contact Lens MarketMarket Growth

Big Data in Power Sector MarketMarket

Floor Scrubber MarketMarket Share

Lighters MarketMarket Growth Rate

Prescription Pet Food MarketMarket Forecast

Global Skim Milk Powder (SMP) MarketMarket Size

Automatic Digital Cockpit IT Service MarketMarket Growth

Sapphire MarketMarket Analysis

Chloroprene Rubber (CR) MarketMarket Size

Global Electric Vehicle Charging Station MarketMarket Share

Global Molten Salt Solar Energy Thermal Storage and Concentrated Solar Power CSP MarketMarket Growth

Mechanical Microkeratome MarketMarket

Dual Teacher Teaching MarketMarket Share

Lighter MarketMarket Growth Rate

Three Season Sunroom MarketMarket Forecast

Global Amorphous Fe MarketMarket Size